207 related articles for article (PubMed ID: 8632330)
1. Assessment of the involvement of central nervous system and peripheral opioid receptors in the immunomodulatory effects of acute morphine treatment in rats.
Fecho K; Maslonek KA; Dykstra LA; Lysle DT
J Pharmacol Exp Ther; 1996 Feb; 276(2):626-36. PubMed ID: 8632330
[TBL] [Abstract][Full Text] [Related]
2. Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats.
Fecho K; Maslonek KA; Dykstra LA; Lysle DT
J Pharmacol Exp Ther; 1996 May; 277(2):633-45. PubMed ID: 8627540
[TBL] [Abstract][Full Text] [Related]
3. Alterations of immune status induced by the sympathetic nervous system: immunomodulatory effects of DMPP alone and in combination with morphine.
Fecho K; Maslonek KA; Dykstra LA; Lysle DT
Brain Behav Immun; 1993 Sep; 7(3):253-70. PubMed ID: 8219413
[TBL] [Abstract][Full Text] [Related]
4. Evidence for the involvement of the caudal region of the periaqueductal gray in a subset of morphine-induced alterations of immune status.
Lysle DT; Hoffman KE; Dykstra LA
J Pharmacol Exp Ther; 1996 Jun; 277(3):1533-40. PubMed ID: 8667220
[TBL] [Abstract][Full Text] [Related]
5. Morphine-induced alterations of immune status: dose dependency, compartment specificity and antagonism by naltrexone.
Lysle DT; Coussons ME; Watts VJ; Bennett EH; Dykstra LA
J Pharmacol Exp Ther; 1993 Jun; 265(3):1071-8. PubMed ID: 7685383
[TBL] [Abstract][Full Text] [Related]
6. Neuropeptide Y Y1 receptors mediate morphine-induced reductions of natural killer cell activity.
Saurer TB; Ijames SG; Lysle DT
J Neuroimmunol; 2006 Aug; 177(1-2):18-26. PubMed ID: 16766046
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic analysis of splenocyte subsets following acute morphine treatment in the rat.
Fecho K; Lysle DT
Cell Immunol; 1999 Aug; 195(2):137-46. PubMed ID: 10448013
[TBL] [Abstract][Full Text] [Related]
8. Acetylcholinesterase monoclonal antibody-induced sympathectomy: effects on immune status and acute morphine-induced immunomodulation.
Fecho K; Maslonek KA; Dykstra LA; Lysle DT
Brain Behav Immun; 1997 Sep; 11(3):167-84. PubMed ID: 9417803
[TBL] [Abstract][Full Text] [Related]
9. GABA and opioid mechanisms of the central amygdala underlie the withdrawal-potentiated startle from acute morphine.
Cabral A; Ruggiero RN; Nobre MJ; Brandão ML; Castilho VM
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):334-44. PubMed ID: 19150477
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine produces naltrexone reversible alterations of immune status.
Carrigan KA; Saurer TB; Ijames SG; Lysle DT
Int Immunopharmacol; 2004 Mar; 4(3):419-28. PubMed ID: 15037219
[TBL] [Abstract][Full Text] [Related]
11. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
12. Suppression of natural killer cell activity by morphine is mediated by the nucleus accumbens shell.
Saurer TB; Carrigan KA; Ijames SG; Lysle DT
J Neuroimmunol; 2006 Apr; 173(1-2):3-11. PubMed ID: 16364456
[TBL] [Abstract][Full Text] [Related]
13. The effects of morphine, nicotine and epibatidine on lymphocyte activity and hypothalamic-pituitary-adrenal axis responses.
Mellon RD; Bayer BM
J Pharmacol Exp Ther; 1999 Feb; 288(2):635-42. PubMed ID: 9918569
[TBL] [Abstract][Full Text] [Related]
14. Opioid-induced suppression of rat testicular function.
Adams ML; Sewing B; Forman JB; Meyer ER; Cicero TJ
J Pharmacol Exp Ther; 1993 Jul; 266(1):323-8. PubMed ID: 8392556
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone-induced conditioned place aversion following a single dose of morphine in the rat.
White DA; Hwang ML; Holtzman SG
Pharmacol Biochem Behav; 2005 Jul; 81(3):451-8. PubMed ID: 15907990
[TBL] [Abstract][Full Text] [Related]
16. Suppression of lymphocyte activity after acute morphine administration appears to be glucocorticoid independent.
Bayer BM; Hernandez M; Irvin L
Prog Clin Biol Res; 1990; 325():273-82. PubMed ID: 2153984
[No Abstract] [Full Text] [Related]
17. Alpha adrenergic and mu-2 opioid receptors are involved in morphine-induced suppression of splenocyte natural killer activity.
Carr DJ; Gebhardt BM; Paul D
J Pharmacol Exp Ther; 1993 Mar; 264(3):1179-86. PubMed ID: 8383741
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression by morphine is mediated by central pathways.
Hernandez MC; Flores LR; Bayer BM
J Pharmacol Exp Ther; 1993 Dec; 267(3):1336-41. PubMed ID: 8263796
[TBL] [Abstract][Full Text] [Related]
19. DAMGO and 6beta-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens.
Al-Khrasani M; Spetea M; Friedmann T; Riba P; Király K; Schmidhammer H; Furst S
Brain Res Bull; 2007 Oct; 74(5):369-75. PubMed ID: 17845912
[TBL] [Abstract][Full Text] [Related]
20. Pavlovian conditioning of morphine-induced alterations of immune status: evidence for opioid receptor involvement.
Coussons-Read ME; Dykstra LA; Lysle DT
J Neuroimmunol; 1994 Dec; 55(2):135-42. PubMed ID: 7829663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
